

Author Index Volume 21 (2009)

The issue number is given in front of the page numbers.

- Aggarwal, R., see Brodie, A. (4) 201–215
Alvan, G., see Barnes, H.J. (1,2) 13– 22
- Bailey, M., see Brodie, A. (4) 201–215
Barnes, H.J., G. Ragnarsson and G. Alvan, Quality and safety considerations for recombinant biological medicines: A regulatory perspective (1,2) 13– 22
Brodie, A., J. Kinross, M. Bailey, R. Aggarwal and C. Vincent, Using Failure Mode and Effects Analysis to identify hazards within resuscitation (4) 201–215
Bukharie, H.A., Can we prevent fatalities due to antituberculous drugs? (3) 153–160
Buttigieg, G.G., see Savona-Ventura, C. (3) 147–152
Buttigieg, G.G., see Savona-Ventura, C. (4) 177–184
- Chandwani, H., see Gogtay, N.J. (1,2) 23– 30
Chen, Y., Z.A. Wu, C. Zhang and Z. Wu, Overview of safety monitoring of biologicals in China (1,2) 69– 74
Chopra, D., see Rehan, H.S. (4) 229–234
- D’Arcy, E. and R. Moynihan, Can the relationship between doctors and drug companies ever be a healthy one? (4) 185–191
Dhingra, M.S., see Gogtay, N.J. (1,2) 23– 30
Dukes, M.N.G., Tainted blood in Canada: An extraordinary history (1,2) 89– 92
- Felice, N., see Savona-Ventura, C. (4) 177–184
Fukushima, M., see Nishimura, T. (3) 161–167
- Gatt, M., see Savona-Ventura, C. (3) 147–152
Gatt, M., see Savona-Ventura, C. (4) 177–184
Giezen, T.J., S.M.J.M. Straus and A.K. Mantel-Teeuwisse, Pharmacovigilance of biosimilars from a regulatory point of view: Is there a need for a specific approach? (1,2) 53– 58
Gogtay, N.J., M.S. Dhingra, A. Yadav and H. Chandwani, Vaccine policy, regulations and safety in India (1,2) 23– 30
Gulliamier, R.A., see Savona-Ventura, C. (4) 177–184
- Hama, R., Biologicals in Japan (1,2) 59– 68
Hotouras, A., see Looseley, A. (3) 131–137
- Keogh, M., see Looseley, A. (3) 131–137
Kilpatrick, C., WHO save lives: Clean your hands (4) 235–236
Kinross, J., see Brodie, A. (4) 201–215
Kruszewski, S.P., see Paczynski, R.P. (3) 139–145

- Lekkerkerker, F., Are there safety concerns for biosimilars? (1,2) 47– 52
- Löfgren, H., The global biopharma industry and the rise of Indian drug multinationals: Implications for Australian generics policy (1,2) 31– 40
- Looseley, A., A. Hotouras and M. Keogh, Patient safety and the aviation model: Medicine is still learning (3) 131–137
- Lovaglio, P.G., Patient safety monitoring systems using regional administrative data (4) 217–227
- Mantel-Teeuwisse, A.K., see Giezen, T.J. (1,2) 53– 58
- Moynihan, R., see D'Arcy, E. (4) 185–191
- Nishimura, T., H. Tada and M. Fukushima, Lessons from gefitinib-induced interstitial lung disease: Pharmacovigilance for erlotinib in Japan (3) 161–167
- Nyazov, R.R., see Ziganshina, L.E. (1,2) 75– 88
- Paczynski, R.P. and S.P. Kruszewski, A link between schizophrenia and diabetes?: Insights from the pre-antipsychotic era (3) 139–145
- Ragnarsson, G., see Barnes, H.J. (1,2) 13– 22
- Rägo, L., Biosimilar medicines and safety: New challenges for pharmacovigilance (1,2) 5– 11
- Rastogi, S., Poor quality and improper use: A review of common reasons of possible adversity in Ayurvedic practice (3) 121–130
- Rehan, H.S. and D. Chopra, Guide to reporting adverse drug reactions (4) 229–234
- Rossignol, N., How the European Union reviews and approves 'follow-on biologics' or biosimilar products (1,2) 105–109
- Savona-Ventura, C., G.G. Buttigieg, N. Felice, R.A. Gulliamier and M. Gatt, Risk factors for prematurity in the Maltese Islands: 1999–2006 (4) 177–184
- Savona-Ventura, C., G.G. Buttigieg and M. Gatt, Obstetric outcomes in immigrants of African nationality (3) 147–152
- Schück, S. and N. Texier, Biosimilars: The French policy (1,2) 41– 45
- Straus, S.M.J.M., see Giezen, T.J. (1,2) 53– 58
- Sweileh, W.M., Pain medications in Palestinian households: Safety and wastage analysis (4) 193–200
- Tada, H., see Nishimura, T. (3) 161–167
- Texier, N., see Schück, S. (1,2) 41– 45
- Usdin, S., The Heparin Story (1,2) 93–103
- Vincent, C., see Brodie, A. (4) 201–215
- Wu, Z., see Chen, Y. (1,2) 69– 74
- Wu, Z.A., see Chen, Y. (1,2) 69– 74
- Yadav, A., see Gogtay, N.J. (1,2) 23– 30
- Zhang, C., see Chen, Y. (1,2) 69– 74
- Ziganshin, A.U., see Ziganshina, L.E. (1,2) 75– 88
- Ziganshina, L.E., R.R. Nyazov and A.U. Ziganshin, Biopharmaceuticals in the Russian Federation: A snapshot of policies for registration, reimbursement and use (1,2) 75– 88